Loading clinical trials...
Loading clinical trials...
Clinical Trial to Investigate Superiority of HLA Matching in Comparison to Random Graft Assignment With Respect to the Endpoint 'Time to First Endothelial Graft Rejection' in Penetrating Keratoplasty.
Penetrating keratoplasty is one of the most commonly performed transplantation surgeries. Graft rejection is a major complication. HLA compatibility has already been demonstrated an effective prophylaxis in several retrospective investigations. The purpose of the investigators randomized clinical trial is to demonstrate superiority of HLA matching in comparison to random graft assignment with respect to the endpoint 'time to first endothelial graft rejection' in penetrating keratoplasty. The investigators will perform DNA-based allele resolution typing.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University Eye Hospital Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Start Date
September 1, 2009
Primary Completion Date
May 1, 2015
Completion Date
May 1, 2015
Last Updated
October 25, 2016
650
ESTIMATED participants
HLA Matching
OTHER
Penetrating keratoplasty
PROCEDURE
Lead Sponsor
University Hospital Freiburg
Collaborators
NCT06983652
NCT06451172
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions